GlassScriptPhysician profile
Matthew R Hanson
NPI 1285896829
$3,834.26
in general payments reported to CMS, 2019-2025
25 companies · $593 in 2025
The $593 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,289 · 2020: $170 · 2021: $49.23 · 2022: $568 · 2023: $551 · 2024: $613 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,742 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,742.05 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,115.00 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $500.92 | 2019-2025 | |
| Janssen Biotech, INC. | $317.60 | 2019-2024 | Simponi Aria, Remicade, Stelara |
| Dermavant Sciences, INC. | $275.57 | 2023-2024 | Vtama |
| Leo Pharma INC. | $222.61 | 2019-2025 | Adbry, Anzupgo |
| Pfizer INC. | $177.21 | 2019-2024 | |
| Ucb, INC. | $167.24 | 2019-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $164.88 | 2023-2025 | Sotyktu |
| Genzyme Corporation | $146.13 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $130.19 | 2019-2024 | Dupixent |
| Incyte Corporation | $121.50 | 2022-2024 | Opzelura |
| Lilly USA, LLC | $93.09 | 2019-2023 | Taltz, Olumiant |
| Celgene Corporation | $88.35 | 2019 | |
| Amgen INC. | $53.73 | 2023 | Otezla |
| Organon LLC | $40.28 | 2025 | Vtama |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $36.80 | 2023-2025 | Aklief, Epsolay |
| Sun Pharmaceutical Industries INC. | $36.46 | 2019-2023 | Ilumya |
| Bard Peripheral Vascular, INC. | $26.72 | 2025 | Venclose Maven Catheter |
| Genentech USA, INC. | $22.18 | 2019 | |
| Vyne Pharmaceuticals INC. | $20.70 | 2020 | |
| Mayne Pharma Commercial LLC | $17.29 | 2019 | |
| Biofrontera INC. | $16.33 | 2019 | |
| Strata Skin Sciences, INC. | $15.25 | 2025 | Xtrac |
| Fresenius Kabi USA, LLC | $14.52 | 2024 | Idacio |
| Almirall LLC | $13.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Hanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.